1 The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction James H. Barger, MD SAPC Medical Director and Science Officer Desiree A. Crevecoeur-MacPhail, Ph.D. Research Psychologist, UCLA ISAP
2 How Do Drugs Act on the Brain?
3 Changes in Brain Chemistry Drugs of abuse produce their effects by altering brain chemistry. Neurotransmitters and associated receptors responsible for everyday functions are altered by the consumption of drugs. Some of the changes in neurotransmitter activity have a clear relationship to the desired effects of using.
4 Natural Reward vs. Substance-Induced Reward Dopamine transmission: Natural reinforcer People seek out experiences that feel good. These experiences are natural reinforcers. Natural reinforcers stimulate release of dopamine. Dopamine transmission: Substance-induced Nearly all drugs of abuse also increase dopamine availability. 1-2 Dopamine release in the nucleus accumbens is 3-5 times greater for substances than natural reinforcers. 3
5 Addiction as a Brain Disease Many drugs of abuse can cause lasting changes to brain chemistry, particularly the dopamine reward pathway. Limited availability of dopamine in key regions of the brain may desensitize the reward circuit to natural reinforcers. Clients may choose continued substance use to overcome a deficit in dopamine availability.
6 Naltrexone and Other Medications
7 Medications for Alcohol Use Disorders Antabuse (Disulfiram) Interrupts the metabolism of alcohol Creates an unpleasant physical reaction Acamprosate (Campral) Glutamate excitability associated with physiological craving Believed to decrease cravings by normalizing GABA and glutamate
8 Medications for Opiate Use Disorders Methadone High doses of methadone alleviate patient cravings for opioids. Daily dosing required due to risk of withdrawal when time between dosing exceeds 36 hours. Suboxone= Buprenorphine + Naloxone Naloxone combined with Buprenorphine to reduce potential for abuse Naloxone is a powerful opioid receptor antagonist that will displace other opioids and precipitate withdrawal.
9 Oral Naltrexone (Revia) Approved by the FDA for alcohol dependence in 1984 Naltrexone is an opiate receptor antagonist that dampens the perceived reward or pleasure of drinking. Naltrexone interferes with dopamine transmission and diminishes the perceived reinforcing effects of alcohol.
10 What is Vivitrol? Injectable extended release naltrexone was FDA approved in 2006, for the treatment of alcoholism In 2011, the FDA approved Vivitrol for the treatment of opiate addiction. An opioid receptor antagonist, that blocks the mu-opioid receptors in the brain Mu-opioid receptors are responsible for the high or buzz individuals feel when alcohol is consumed or opiates are used.
11 Partial/Full Agonist, Antagonist, What s the Difference?
12 Agonist Medications Have similar structure and bind to same receptor sites as drug of abuse Provide full activation at receptor site where it binds Example: Methadone is a full agonist a synthetic opioid that binds to the receptors activated by heroin and other opioids Occupies mu opioid receptor Provides relief from craving and withdrawal If taken as prescribed, user does not experience euphoria or intoxication
13 Partial Agonist Medications Similar structure and bind to same receptor sites as drug of abuse Provide partial activation at receptor site Provide relief from craving and withdrawal Degree of activation less than a full agonist Block full agonists from binding at receptor sites Limit drug s effect if substance is subsequently used Example: Buprenorphine is a partial agonist at the mu opioid receptor
14 Antagonist Medications Decrease pleasure and reward from drug use Have similar structure and bind to same receptor sites as drug of abuse Provide no activation at receptor site where it binds Block full and partial agonists from binding at receptor sites May induce withdrawal symptoms when full agonist drugs are displaced by antagonist medication
15 Vivitrol is a Mu Opioid Receptor Antagonist
16 Precautions with Vivitrol Client must be abstinent from all opiates for at least 10 days. Ideally, client must be abstinent from alcohol for at least 7 days. Not approved for anyone under 18 or pregnant or nursing women Not approved for anyone with active hepatitis or elevated liver enzymes
17 Benefits of Vivitrol Reduces the number of risky and heavy drinking days (Garbutt et al., 2005; Lee et al., 2010; Manelli, 2007) Effective in relapse prevention for heroin users (Krupitsky, & Blokhina, 2010). Improves individuals quality of life (Pettinati et al., 2009; Schmitz et al., 2001).
18 Combining Counseling with Medication Medications enhance the effectiveness of counseling Improved compliance in methadone maintenance Augmenting cognitive behavioral therapy with naltrexone increases periods of abstinence and decreases rates of heavy drinking Ease discomfort of withdrawal symptoms in early recovery associated with improved retention
19 Resistance to Medications Common reasons given for client resistance to medication 1.Anticipated unpleasant side effects 2.Cost of medication 3.Burden of taking daily medication 4.Denial about condition or disease 5.Influence of others 6.Negative perception of addiction medications
20 Los Angeles County Vivitrol Pilot Project
21 Evaluation Questions Do LA County SAPC clients remain on Vivitrol beyond the 1st dose? Does medication affect client outcomes? Length of stay, reported use of alcohol, retention and engagement Does staff knowledge and attitudes toward medication assisted treatment improve at 4 month follow-up compared to baseline, as a result of trainings?
22 Evaluation Design The three medication hubs: Tarzana Treatment Center (main hub) Behavioral Health Services Prototypes. Selection criteria: Infrastructure (staff, examination room, refrigerated and locked location for medication storage) to administer medications Long-standing histories of providing quality substance abuse treatment to a broad range of clients
23 Treatment Outcome Data Methods Los Angeles County Participant Reporting System (LACPRS) Patient Response to Vivitrol Medically Assisted Treatment Survey (MATS) Urge to Drink Scale (UDS) Counselors Attitude Counselor Attitude Survey Staff at treatment sites would gather the required data and submit to UCLA for analysis
24 Results and Conclusions All Results Significant at p<.05 or better
25 Participant Characteristics Overall N (%) Detoxification Participants n (%) Treatment Participants n (%) Total 387 (100%) 96 (24.8%) 233 (60.2%) Male 195 (50.4%) 65 (67.7%) 101 (43.3%) Female 192 (49.6%) 31 (32.3% 132 (56.7%) Race/Ethnicity White 205 (53%) 65 (67.7%) 103 (44.2%) Hispanic/Latino 124 (32%) 22 (22.9%) 90 (38.6%) African American 38 (9.8%) 2 (2.1%) 30 (12.9%) Asian American/Pacific Islander 5 (1.3%) 4 (2.0%) 0 (0.0% American Indian/Alaskan Native 3 (0.8%) 1 (1.0%) 2 (0.9%) Other 12 (3.1%) 2 (2.1%) 8 (3.4%) Mean Age 38.0 years 39.8 years 27.9 years
26 Vivitrol Doses by Site Total (N=399) Tarzana (n=290) Prototypes (n=39) BHS (n=70) Average # of Doses Mode Minimum # of Doses Maximum # of Doses Injections Received One Dose Only, % (n) 41.1% (164) 45.5% (132) 28.2% (11) 30.0% (21) Two Doses Only, % (n) 22.6% (90) 22.1% (64) 30.8% (12) 20.0% (14) Three Doses Only, % (n) 12.3% (49) 11.4% (33) 15.4% (6) 13.3% (10) Four or More Doses, % (n) 24.0% (96) 21.0% (61) 25.6% (10) 36.7% (26)
27 Reduced Urge to Drink Based on the Urge to Drink Scale, which is scored from 0 to 30.
28 Limited Side Effects Proportion Reporting Side Effect for Weeks 1 4 After First Dose
29 Treatment Clients Reduced Primary Drug Use Reduction in Primary Drug Use Days for Treatment (In Past 30 Days) Mean Days in Past All Treatment Clients Outpatient Clients Residential Clients Admission Discharge
30 Higher Abstinence Rates among Vivitrol Treatment Clients Reduction in Primary Drug Use Days for Treatment (In Past 30 Days) % Abstinent at Discharge % 83.1% 81.6% 90.3% 0 Outpatient County Average Residential Vivitrol Treatment Clients
31 Higher Engagement Rates among Vivitrol Treatment Clients Engagement Rates of L.A. County Clients vs. Vivitrol Treatment Clients % 88.2% 79.6% 94.3% % Engagement % 64.2% 25 0 Overall Outpatient Residential County Average Vivitrol Treatment Clients
32 Higher Completion Rates among Vivitrol Treatment Clients 100 Completion Rates of L.A. County Clients vs. Vivitrol Treatment Clients % Completed % 33.6% 32.9% 46.6% 39.2% 64.1% 25 0 Overall Outpatient Residential County Average Vivitrol Treatment Clients
33 Improved Counselor Attitudes Counselor attitudes improved over the course of the project and many who initially reported neutral or negative attitudes towards medication-assisted treatment in general or Vivitrol in particular, reported positive attitudes on the follow-up survey.
34 Take Away Points Good medication adherence: 68% Few side effects: Less than 25% reported any single side effect. Decrease Use: Clients reported significant decreases in alcohol use reducing their use from 17 days to less than 2 days per month in the past 30 days.
35 Success Stories
36 45-year-old, Latina female who has been trying to stop drinking for 15 years. She has been in over 20 detoxes and this is her fifth time in residential treatment. This is the first time, thanks to Vivitrol, that she has lost the craving for alcohol since she began drinking as an adolescent.
37 52-year-old, Caucasian male who has been drinking since 14 years of age. He tried to stop drinking for 25 years on his own or through 12-step programs. He never achieved more than 3-4 months of sobriety at a time. This is his 2 nd Tx program; in his first program he lasted two months thinking about drinking every single day. I couldn t get it out of my head, so I left. Currently, he has received 2 Vivitrol injections and has been able to concentrate on the counseling work since the third day after his first injection. He was on a pass last week and passed the liquor store where he has been keeping a tab for 15 years and didn t even realize I went by it until I was three blocks away. Vivitrol is fantastic!
38 36-year-old, American Indian male with a 20-year history of alcohol and methamphetamine abuse and a co occurring diagnosis of bipolar disorder. He has been in treatment 4 times since he began trying to stop using 8 years ago. While he did manage to stop using meth 4 years ago, his daily drinking has been steadily getting worse over the last two years, most often leading to blackouts. He has received 4 Vivitrol injections so far and says he has not had any urges to drink since a couple of days after the first shot.
39 In this pilot, Vivitrol Conclusions Increased the number of clients who complete treatment in detoxification, outpatient counseling and residential treatment programs. Decreasing substance use in outpatient counseling and residential treatment Increasing treatment engagement (outpatient and residential) and treatment continuance for residential treatment.
40 Next Steps Write up results for presentations at conferences and meetings as well as for journal publications Assess urges once Vivitrol is no longer being taken short-term follow-up Address Board Amendments
41 Current Study: Follow-Up Collect UDS and MATs on new clients Conduct 30 and 60 day post final dose followups to examine Pattern in urges to drink/use Do urges return at same level, lower level or higher Examine reported patterns of use Is sobriety that is earned in treatment maintained after treatment ends Interviews and drug tests
42 Los Angeles County Board of Supervisors Amendments SAPC to report in 90 days on: 1. Policy changes needed to expand the availability of Vivitrol (Medi-Cal) 2. Recommendations on how Vivitrol can be purchased at the most affordable price SAPC to report in 12 Months on: 1. The efficacy of Vivitrol and MAT as cost effective measures to improve outcomes 2. Recommendations for use in high risk, high consequence populations
43 Acknowledgements For allowing the use of their slides, thanks to Eric Devine, Ph.D. is and Assistant Professor of Psychiatry at the Boston University School of Medicine and training Faculty for the Boston Center for Treatment Development and Training (BCTDT). Join Together is a program of the Boston University School of Public Health.
45 Thank You! James H. Barger, MD (626) Desiree A. Crevecoeur-MacPhail, Ph.D. (310)
Extended-Release Injectable Naltrexone (Vivitrol) Pilot Project in Los Angeles County John Viernes, Jr. Executive Director Substance Abuse Prevention and Control (SAPC) Los Angeles County Department of
Use of Vivitrol for Alcohol and Opioid Addiction Ken Bachrach, Ph.D. Clinical Director, Tarzana Treatment Centers, Inc. firstname.lastname@example.org What is Vivitrol? An injectable from of naltrexone, which
Vivitrol Pilot Study: SEMCA/Treatment Providers Collaborative Efforts with the treatment of Opioid Dependent Clients Hakeem Lumumba, PhD, CAADC SEMCA Scott Schadel, MSW, LMSW, CAADC HEGIRA PROGRAMS, INC.
Beyond SBIRT: Integrating Addiction Medicine into Primary Care Community Clinic Association of Los Angeles County 14 th Annual Health Care Symposium March 6, 2015 Keith Heinzerling MD, Karen Lamp MD; Allison
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate
Medications for Alcohol and Drug Dependence Treatment Robert P. Schwartz, M.D. Medical Director Rschwartz@friendsresearch.org Friends Research Institute Medications for Alcohol Dependence Treatment Disulfiram
Advanced Treatment for Opioid & Alcohol Dependence John Larson, M.D. Corporate Medical Director Gateway Foundation Background 41 years practicing psychiatry Last 15 in addiction medicine I ve watched a
Page: 1 of 7 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction March 3, 2008 By: David Rinaldo, Ph.D., Managing Partner, The Avisa Group In this FAQ What medications are currently
DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please
Use of Pharmacotherapies by Substance Abuse Treatment Facilities Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration Department of Health and Human Services November 2007 1
Naltrexone and Alcoholism Treatment Test Following your reading of the course material found in TIP No. 28. Please read the following statements and indicate the correct answer on the answer sheet. A score
Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call the
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence
Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism Richard A. Rawson, Ph.D, Professor Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine University
Heroin Overdose Trends and Treatment Options Neil A. Capretto, D.O., F.A.S.A.M. Medical Director Type date here www.gatewayrehab.org Drug Overdose Deaths Increasing in Allegheny County Roberta Lojak holds
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently asked questions What is Naltrexone? Naltrexone is a prescription drug that completely blocks the effects of all opioid drugs
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently Asked Questions What is Naltrexone? Naltrexone is a prescription drug that effectively blocks the effects of heroin, alcohol,
Medications for Alcohol and Opioid Use Disorders Andrew J. Saxon, M.D. Center of Excellence in Substance Abuse Treatment and Education (CESATE) VA Puget Sound Health Care System Alcohol Pharmacotherapy
Buprenorphine Therapy in Addiction Treatment Ken Roy, MD, FASAM Addiction Recovery Resources, Inc. River Oaks Hospital Tulane Department of Psychiatry www.arrno.org Like Minded Doc What is MAT? Definition
M00K02 Alcohol and Drug Abuse Administration Department of Health and Mental Hygiene The Use of Non-Opioid Pharmacotherapies for the Treatment of Alcohol Dependence Introduction The 2011 Joint Chairmen
Brain Damage & Recovery: The Resilience of the Brain, Addiction Impact & Therapeutic Repair Michael Fishman, MD Director of Young Adult Program How Addiction Takes Hold Large & rapid upsurges in dopamine
Substitution Therapy for Opioid Dependence The Role of Suboxone Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Objectives Recognize the options available in treating opioid
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by
Alcohol Overuse and Abuse ACLI Medical Section CME Meeting February 23, 2015 Daniel Z. Lieberman, MD Professor and Vice Chair Department of Psychiatry George Washington University Alcohol OVERVIEW Definitions
Using Drugs to Treat Drug Addiction How it works and why it makes sense Jeff Baxter, MD University of Massachusetts Medical School May 17, 2011 Objectives Biological basis of addiction Is addiction a chronic
PATHWAYS TO RECOVERY PATHWAYS TO RECOVERY When Faces & Voices of Recovery was launched in 2001, our founding goal was to celebrate and honor recovery in all of its diversity. We believe that everyone has
Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious
Medication-Assisted Addiction Treatment Molly Carney, Ph.D., M.B.A. Executive Director Evergreen Treatment Services Seattle, WA What is MAT? MAT is the use of medications, in combination with counseling
Ohio Legislative Service Commission Bill Analysis Brian D. Malachowsky H.B. 378 130th General Assembly () Reps. Smith and Sprague BILL SUMMARY Prohibits a physician from prescribing or personally furnishing
FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma Background A growing opiate abuse epidemic has highlighted the need for effective treatment options. This study documents
Tolerance and Dependence Drug Tolerance is a decrease in the effect of a drug as a consequence of repeated exposure. Change over repeated exposures. Different effects may show different tolerance. Tolerance
Neurobiology and Treatment of Opioid Dependence Nebraska MAT Training September 29, 2011 Top 5 primary illegal drugs for persons age 18 29 entering treatment, % 30 25 20 15 10 Heroin or Prescription Opioids
Diagnosis and Treatment of Alcohol Dependence Lon R. Hays, MD, MBA Professor and Chairman Department of Psychiatry University of Kentucky Medical Center Defining the Standard Drink A standard drink = 14
UCLA-SAPC Lecture Series March 13, 2015 Gary Tsai, M.D. Medical Director Substance Abuse Prevention and Control Neurobiology 101 Neuroscience of Addiction & Recovery Medication-Assisted Treatment (MAT)
Drug Court EPIDEMIC In the 10 years (1997 2007) the per capita retail purchases of Methadone, Hydrocodone and Oxycodone in the United States increased 13-fold, 4-fold and 9-fold, respectively. 4.6 % OF
Medication Assisted Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority Bureau Of Prevention, Treatment, & Recovery State of Wisconsin Elizabeth Collier, MSW, CSAC, ICS, LCSW TANF Best Practice
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Sidarth Wakhlu,M.D. Addiction Team Leader North Texas VA Health Care System Addiction Psychiatry Fellowship Director Associate Professor Of Psychiatry
Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,
Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem Thomas Kosten MD Waggoner Chair & Professor of Psychiatry & Neuroscience Baylor College of Medicine Past-President,
Sarah Akerman MD Assistant Professor of Psychiatry Director of Addiction Services Geisel School of Medicine/Dartmouth-Hitchcock Medical Center OVERVIEW OF MEDICATION ASSISTED TREATMENT Conflicts of Interest
Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation Cynthia Caporizzo, Senior Criminal Justice Advisor, Office of National Drug Control Policy (ONDCP) - Review of the administration
National Survey of Substance Abuse Treatment Services The N-SSATS Report January 28, 2010 Overview of Opioid Treatment Programs within the United States: 2008 In Brief In 2008, a total of 1,132 (8 of all
This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)
1 Chapter 36. Substance-Related, Self-Assessment Questions 1. According to recent US national estimates, which of the following substances is associated with the highest incidence of new drug initiates
Understanding Addiction: Squirrel Logic Brad Lander PhD, LICDC Clinical Director / Psychologist Talbot Hall Addiction Medicine at The Ohio State University Wexner Medical Center Addiction Lack of ability
Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Dale K. Adair, MD Medical Director/Chief Psychiatric Officer OMHSAS 1 Treatment and Interventions for
Facts About Opioid Overdose How Does an Overdose Occur? Opioid overdose can occur when a patient misunderstands the directions for use, accidentally takes an extra dose, or deliberately misuses a prescription
Joel Millard, DSW, LCSW Dave Felt, LCSW 1. Provide an overview of the effectiveness of medication assisted treatment, to include a discussion of the different types of medications and how they are used
Opioid/Opiate Dependent Pregnant Women The epidemic, safety, stigma, and how to help. Presented by Lisa Ramirez MA,LCDC & Kerby Stewart MD The prescription painkiller epidemic is killing more women than
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings From Starting Treatment With Agonist Replacement Therapies (START) Jennifer
NIAA Research Findings Summary: National Institute on Alcohol Abuse and Alcoholism (NIAAA) Research Findings Orientation to Naltrexone and the Integration of Medication into State Treatment Systems. Posted
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
Effective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Naltrexone (Vivitrol ) Injections Policy #: 457 Latest Review
Medication is not a part of treatment. Medication can be an effective part of treatment. Medication is used in the treatment of many diseases, including addiction. Medical decisions must be made by trained
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Mark Fisher Program Administrator State Opioid Treatment Adminstrator Kentucky Division of Behavioral Health OBJECTIVES Learn about types of opioids and
Best Practices in Opioid Dependence Treatment Anthony L. Jordan Health Center Linda Clark, MD, MS Medical Director Alana Ramos, BS Suboxone Clinic Manager Case Studies Nicole White female 27 years of age
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
SC 215 FIGHTING DRUG ADDICTION WITH DRUGS John Bush April 15, 2013 ADDICTION A persistent, compulsive dependence on a behavior or substance Behavioral Compulsive shopping --Compulsive eating Compulsive
John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemic
Developing Medications to Treat Addiction: Implications for Policy and Practice Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine
Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,
Alcohol Abuse and Dependence in Native Americans Its link to suicide and medication treatment options Addiction Psychiatrist Objectives Will discuss alcohol s role in suicide with the limited data we have.
Professional Intervention and Treatment Related to Opioid Misuse and Addiction Michael M. Miller, MD, FASAM, FAPA Drug Poisoning Summit: Stop the Overdose Epidemic January 30, 2012 University of Wisconsin
Heroin Heroin is a synthetic opiate drug that is highly addictive. It is made from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears
Heroin Introduction Heroin is a powerful drug that affects the brain. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she wants to.
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing
H-SOAP STUDY Hospital-based Services for Opioid- and Alcohol-addicted Patients Meldon Kahan, Anita Srivastava, Kate Hardy, Sarah Clarke Canadian Society of Addiction Medicine 2014 October 17, 2014 1 Few
Module 2: Understanding Addiction, Recovery, and Recovery Oriented Systems of Care This module reviews the processes involved in addiction and what is involved in recovering an addiction free lifestyle.
Who We Are BHG s Medical Mission BHG Company Overview Behavioral Health Group (BHG) is a leading provider of opioid addiction treatment services. Our treatment centers provide pharmacotherapeutic maintenance
opiates alcohol 27 opiates and alcohol 30 April 2016 drug addiction signs 42 ed #1 123 Drug Rehab Centers in New Jersey 100 Top 10 380 effects of alcohol in the brain 100 Top 30 698 heroin addiction 100
Medications to address the opioid crisis - methadone, buprenorphine, naltrexone, and naloxone Alexander Y. Walley, MD, MSc Director, Addiction Medicine Fellowship and Addiction Medicine Consult Service
Addiction Messenger Part 1: - Setting the Context "When you love someone who suffers from the disease of addiction you await the phone call. There will be a phone call. T he sincere hope is that the call
Reintegration Recovery Medication-Assisted Treatment for Alcohol Dependence Reintegration Resilience 02 How do you free yourself from the stress and risks of alcohol dependence? Most people cannot do it
Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society